These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12218236)

  • 1. Pityriasis rosea associated with imatinib (STI571, Gleevec).
    Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
    Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
    Brouard MC; Prins C; Mach-Pascual S; Saurat JH
    Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome after treatment with STI571: a case report.
    Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
    Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
    Brazzelli V; Prestinari F; Roveda E; Barbagallo T; Bellani E; Vassallo C; Orlandi E; Passamonti F; Borroni G
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S240-3. PubMed ID: 16227099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral lichenoid reaction to imatinib (STI 571, Gleevec).
    Lim DS; Muir J
    Dermatology; 2002; 205(2):169-71. PubMed ID: 12218235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
    Park MA; Volcheck GW; Guarderas JC
    Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 12. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 13. Follicular mucinosis associated with imatinib (STI571).
    Yanagi T; Sawamura D; Shimizu H
    Br J Dermatol; 2004 Dec; 151(6):1276-8. PubMed ID: 15606531
    [No Abstract]   [Full Text] [Related]  

  • 14. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features of pityriasis rosea-like drug eruption secondary to imatinib: A case report and review of the literature.
    Durgin JS; Whittington CP; Harrell J; Mervak JE; Smith EH
    J Cutan Pathol; 2024 Nov; 51(11):860-865. PubMed ID: 39021288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
    Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
    J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
    Pasmatzi E; Monastirli A; Matsouka P; Tsambaos D
    Acta Derm Venereol; 2003; 83(5):391-2. PubMed ID: 14609118
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.